Babylon hires Andrew Hine to spearhead overseas expansion UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as Share X Babylon hires Andrew Hine to spearhead overseas expansion https://pharmaphorum.com/news/babylon-hires-andrew-hine-to-spearhead-overseas-expansion/
Merck defends blockbuster Januvia franchise from patent challenge Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition Share X Merck defends blockbuster Januvia franchise from patent challenge https://pharmaphorum.com/news/merck-defends-blockbuster-januvia-franchise-from-patent-challenge/
Relief for Amylyx as FDA clears controversial ALS drug Relyvrio Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after Share X Relief for Amylyx as FDA clears controversial ALS drug Relyvrio https://pharmaphorum.com/news/relief-for-amylyx-as-fda-clears-controversial-als-drug-relyvrio/
Frontiers Health Steering Committee spotlight: Eugene Borukhovich With Frontiers Health 2022 mere weeks away, we continue to interview members of the steering committee, gaining insight Share X Frontiers Health Steering Committee spotlight: Eugene Borukhovich https://pharmaphorum.com/views-and-analysis/frontiers-health-steering-committee-spotlight-eugene-borukhovich/
Low-Priced Oncology Disruptors: The Cuckoo in the PD-1/PD-L1 Nest or the Runt of the Clutch? Part I Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and Share X Low-Priced Oncology Disruptors: The Cuckoo in the PD-1/PD-L1 Nest or the Runt of the Clutch? https://pharmaphorum.com/views-and-analysis/low-priced-oncology-disruptors-the-cuckoo-in-the-pd-1-pd-l1-nest-or-the-runt/
Moving to component management & traceability: progress, barriers, and the way forward Component management is fairly new to the regulatory market, with pharmaceutical firms moving from traditional document management systems Share X Moving to component management & traceability: progress, barriers, and the way forward https://pharmaphorum.com/views-and-analysis/moving-to-component-management-traceability-progress-barriers-and-the-way-forward/
Deep Dive: Communications & Commercialisation 2022 There is little doubt that the arrival of COVID-19 changed the game for communication and commercialisation efforts for Share X Deep Dive: Communications & Commercialisation 2022 https://pharmaphorum.com/sales-marketing/deep-dive-communications-commercialisation-2022/
Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes in-person meetings Researchers also dove into socio-economic disparities in cancer care. Last month in Chicago, Illinois the American Society of Share X Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes in-person meetings https://pharmaphorum.com/oncology/checkpoint-inhibitors-enhertu-in-spotlight-as-asco-resumes-in-person-meetings/
New horizons in breast cancer care Interview with Markus Kosch, Daiichi Sankyo head of Oncology Business Division in Europe. Recent progress in immunotherapy, targeted Share X New horizons in breast cancer care https://pharmaphorum.com/oncology/new-horizons-in-breast-cancer-care/
Medical Informatics and Rare Disease: a bridge between two worlds Share X Medical Informatics and Rare Disease: a bridge between two worlds https://pharmaphorum.com/webinars/medical-informatics-bridge-between-two-worlds-iqvia/
ICSs – an opportunity to improve Patient & Market Access at a local level Share X ICSs – an opportunity to improve Patient & Market Access at a local level https://pharmaphorum.com/webinars/integrated-care-systems-opportunity-to-improve-patient-market-access/
Is your digital communication strategy up to par? Share X Is your digital communication strategy up to par? https://pharmaphorum.com/webinars/is-your-digital-communication-strategy-up-to-par/
Pharma’s New Frontier MSLs are in prime position to build new structures of engagement as the pharma industry recalibrates after the Share X Pharma’s New Frontier https://pharmaphorum.com/sales-marketing/pharmas-new-frontier/
Ensuring successful digital outreach and retention in atopic dermatitis trials Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. With more than Share X Ensuring successful digital outreach and retention in atopic dermatitis trials https://pharmaphorum.com/whitepapers/ensuring-successful-digital-outreach-and-retention-atopic-dermatitis-trials/
The value of diverse patient representation and engagement in cancer treatment To improve outcomes for cancer patients and take advantage of the ground-breaking scientific and technological progress made in Share X The value of diverse patient representation and engagement in cancer treatment https://pharmaphorum.com/whitepapers/value-of-diverse-patient-representation-and-engagement-cancer/
Health Innovators – Dr. Houda Hachad Share X Health Innovators – Dr. Houda Hachad https://pharmaphorum.com/video/health-innovators-dr-houda-hachad/
How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast Share X How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast https://pharmaphorum.com/patients/how-a-once-weekly-insulin-could-disrupt-diabetes-management/
Health Innovators – Matt Dugan Share X Health Innovators – Matt Dugan https://pharmaphorum.com/digital/health-innovators-matt-dugan/
Practical advice for Early Scientific Advice (ESA) in HTA submissions Share X Practical advice for Early Scientific Advice (ESA) in HTA submissions https://pharmaphorum.com/partner-content/practical-advice-for-early-scientific-advice-esa-in-hta-submissions/
Influencer Marketing and Social Health: Optimizing Pharma’s Impact Share X Influencer Marketing and Social Health: Optimizing Pharma’s Impact https://pharmaphorum.com/partner-content/influencer-marketing-and-social-health-optimizing-pharmas-impact/
CDISC standards in clinical research Share X CDISC standards in clinical research https://pharmaphorum.com/partner-content/cdisc-standards-in-clinical-research/
KOL Identification Without KOL Mapping Share X KOL Identification Without KOL Mapping https://pharmaphorum.com/partner-content/kol-identification-without-kol-mapping/
AXON hires a Global Healthcare Insights and Strategy Lead Share X AXON hires a Global Healthcare Insights and Strategy Lead https://pharmaphorum.com/partner-content/axon-hires-a-global-healthcare-insights-and-strategy-lead/
Performance-io hires Lonneke Feskens to lead Europe Share X Performance-io hires Lonneke Feskens to lead Europe https://pharmaphorum.com/partner-content/performance-io-hires-lonneke-feskens-to-lead-europe/
